One major cause of the late failure of drugs in development (i.e. attrition) is the lack of clinical safety of the compounds (accounting for approximately 30% of failures together with toxicology). One of the key elements is the off-target effects of the compounds, causing adverse drug reaction (ADRs).
Sorry, this page is available to members only.
If you have not registered with us yet, why not
register today for FREE and receive exclusive online access. Interested in receiving European Pharmaceutical Review in print? Subscribe today and guarantee the next six issues delivered direct to your desk, plus gain exclusive access online.
